Clinical Significance of Outcomes

The magnitude and speed of functional improvement observed in this patient is notable within the context of FSHD as a progressive genetic condition.

FSHD is not known to spontaneously improve or remit. Patients typically experience gradual functional decline over years to decades. In this case, the patient demonstrated immediate functional restoration within 30 minutes of targeted mechanical intervention, with sustained improvements maintained over 3 years.

The breadth of improvement is also notable: bilateral shoulder strength restoration, resolution of foot drop, improvement in multiple systemic symptoms (headaches, tinnitus, vision), and return to recreational activities that were previously impossible.

Neuromyofascial Framework in FSHD

The findings in this case align with a working hypothesis in neuromyofascial science: while FSHD is primarily a genetic myopathy affecting skeletal muscle, patients may develop superimposed mechanical, neuromuscular, or structural contributors that amplify disability. These secondary contributors—such as post-traumatic scarring, segmental restriction, myofascial contracture, or mechanical tethering—may be modifiable through targeted assessment and intervention, even when the primary genetic disease itself cannot be cured.

This framework does not challenge the established understanding that FSHD is a DUX4-mediated genetic myopathy. Rather, it suggests that managing FSHD-related disability may benefit from identifying and treating coexisting mechanical or neuromuscular contributors that can be modified.

The observation that three additional family members with FSHD and similar scapular and limb weakness also underwent TNPC and experienced meaningful functional improvements suggests that neuromyofascial restriction may represent a recurrent pattern worthy of clinical attention in FSHD-affected families, though each case must be individually evaluated and documented.

Comparison to Conventional Surgical Approaches

Scapulothoracic arthrodesis (STA) is a standard surgical approach for severe scapular winging and shoulder elevation limitation in FSHD when deltoid function is preserved. Systematic review data indicate that STA typically achieves improvements in forward elevation of approximately 30–45 degrees, with final postoperative forward flexion ranging from approximately 109–140 degrees. STA carries significant perioperative and long-term risks, including pulmonary complications, hardware failure, nonunion, and revision surgery.

In this case, the patient’s baseline shoulder strength at 3/5 below 80 degrees lateral elevation, with zero power above 80 degrees, progressed to full 180-degree lateral elevation with sustained power. The magnitude of ROM and strength improvement in this case exceeds typical mean gains reported in STA series. However, such comparisons are indirect and have important limitations: STA and TNPC differ in mechanism, indication, patient population, and evidence base. This case is presented not as evidence that TNPC outperforms STA, but rather to highlight that substantial functional improvement occurred through a non-surgical approach in one individual with FSHD.

Limitations and Important Caveats

Causality and temporal association: This is a single case report. The temporal association between TNPC and functional improvement does not establish causation. The magnitude of improvement, its immediate onset within 30 minutes, and its sustained nature over 3 years suggest a clinically meaningful association that warrants further investigation, but alternative explanations cannot be excluded.

Underlying disease: TNPC does not address the underlying genetic myopathy in FSHD. Rather, it targets mechanical spinal restriction and neuromyofascial dysfunction that may be compounding the myopathic deficit. The genetic basis of FSHD remains unmodified by this intervention.

Single case nature: This report documents one patient’s experience. It cannot be generalized to all individuals with FSHD or used to predict outcomes in other patients. Variability in FSHD presentation, coexisting conditions, structural spinal anatomy, and other patient factors would influence both the likelihood of finding neuromyofascial contributors and the response to intervention.

Measurement and assessment limitations: Baseline and post-intervention measurements were performed by the same clinical team that delivered the intervention, creating potential for measurement bias. No blinded independent assessment was conducted. The audit findings represent clinical impression rather than imaging-confirmed pathology. Standardized FSHD outcome measures were not employed.

Alternative explanations: The observed improvements could reflect pain inhibition or guarding reduction, placebo or contextual effects, measurement variability, natural fluctuation in FSHD symptoms, or changes in effort or compensation strategies. These possibilities are not excluded by this single-case presentation.

Maintenance treatments: The patient received periodic TNPC intervals over 3 years, which complicates interpretation of the durability of a single intervention. It is unclear whether the initial treatment alone would have sustained benefits, or whether ongoing periodic care was essential to maintain the observed improvements.

Broader Clinical Implications

If neuromyofascial restriction proves to be a recurrent, identifiable, and treatable contributor to disability in FSHD and related neuromuscular conditions, structured assessment for such pathology and targeted intervention may represent a valuable adjunctive approach to managing disability. This would represent an important shift toward identifying and addressing modifiable mechanical and neuromuscular drivers of functional decline in addition to addressing the primary genetic disease process.

However, such implications remain speculative pending prospective study, independent verification, and systematic investigation in larger FSHD cohorts.